The BIND combined with t‐CNV, mRNA vaccine, IL‐2, and anti‐PD‐1 antibody also significantly enhanced cancer immunotherapy by the dynamic modulation of immunological landscape of tumor microenvironment. This evidence concerns the gene IL2 and cancer.